stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Total debt
Veracyte, Inc.'s total debt at the end of fiscal 2022 was $15.0M, up 1,231.0% from $1.1M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $14.0M. Over the past ten years it has ranged from $1.1M (fiscal 2021) to $25.5M (fiscal 2016); the current reading is higher than 63% of that period. Veracyte, Inc. ranks 32nd of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $15.0M | 1,230.97% |
| FY2021 | $1.1M | (59.89%) |
| FY2020 | $2.8M | 65.88% |
| FY2019 | $1.7M | (93.30%) |
| FY2018 | $25.3M | 0.14% |
| FY2017 | $25.2M | (1.06%) |
| FY2016 | $25.5M | 411.36% |
| FY2015 | $5.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $14.0M | (6.67%) |
| Jun 2023 | $15.0M | 7.14% |
| Mar 2023 | $14.0M | (6.67%) |
| Dec 2022 | $15.0M | 1,163.69% |
| 31 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SHC Sotera Health Company compare | $2.2B |
| RDNT RadNet, Inc. compare | $1.3B |
| NEO NeoGenomics, Inc. compare | $378.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $334.9M |
| WGS GeneDx Holdings Corp. compare | $96.8M |
| BLLN BillionToOne, Inc. compare | $89.1M |
| CDNA CareDx, Inc. compare | $35.2M |
| VCYT Veracyte, Inc. | $14.0M |
| GRAL GRAIL, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement